What did this study find?
This 2024 double-blind pilot examined extremely low frequency pulsed electromagnetic fields in autism spectrum disorder, framed around evidence that inflammation contributes to the condition. The anti-inflammatory effects of the field showed early promise against neuroinflammatory features. Pilot studies are designed to test feasibility, not to establish that a treatment works.
What are the details of this record?
- Full citation
- Effects of Extremely Low-Frequency Electromagnetic Field Treatment on ASD Symptoms in Children: A Pilot Study. PMC. 2024.
- Study design
- Double-blind pilot trial
- Sample size and population
- Not reported in the published record
- Evidence grade
- Grade C+ on the BioReg grading scale
- Reported findings
- Pilot study on ELF-PEMF for ASD. Inflammation plays crucial role in ASD pathophysiology. PEMF's anti-inflammatory effects showed promise in addressing neuroinflammatory components.
- DOI
- No DOI recorded
- PubMed
- Not indexed in PubMed
- Related categories
- Autism Spectrum (category grade C+ to B-)
A positive PEMF study is not evidence for a specific device unless the signal parameters studied, frequency, intensity, waveform, and exposure duration, are reasonably comparable to what that device produces. Where this record does not list those parameters, the source report did not publish them. See the grading methodology. Library last reviewed 2026-08-27.